Your browser doesn't support javascript.
loading
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik, Avraham; Lanzinger, Stefanie; Chia-Hui Tan, Elise; Yabe, Daisuke; Kim, Dae Jung; Sheu, Wayne H-H; Melzer-Cohen, Cheli; Holl, Reinhard W; Ha, Kyoung Hwa; Khunti, Kamlesh; Zaccardi, Francesco; Subramanian, Anuradhaa; Nirantharakumar, Krishnarajah; Nyström, Thomas; Niskanen, Leo; Linnemann Jensen, Majken; Hoti, Fabian; Klement, Riho; Déruaz-Luyet, Anouk; Kyaw, Moe H; Koeneman, Lisette; Vistisen, Dorte; Carstensen, Bendix; Halvorsen, Sigrun; Langslet, Gisle; Fazeli Farsani, Soulmaz; Patorno, Elisabetta; Núñez, Júlio.
Affiliation
  • Karasik A; Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel.
  • Lanzinger S; Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany; German Centre for Diabetes Research (DZD), Neuherberg, München, Germany.
  • Chia-Hui Tan E; Department of Health Service Administration, China Medical University, Taichung, Taiwan.
  • Yabe D; Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan; Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan; Center for Healt
  • Kim DJ; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea.
  • Sheu WH; Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Melzer-Cohen C; Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel.
  • Holl RW; Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany.
  • Ha KH; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea.
  • Khunti K; Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK.
  • Zaccardi F; Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK.
  • Subramanian A; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Nirantharakumar K; Institute of Applied Health Research, University of Birmingham, Birmingham, UK; Midlands Health Data Research UK, Birmingham, UK; DEMAND Hub, University of Birmingham, Birmingham, UK.
  • Nyström T; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden.
  • Niskanen L; Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland.
  • Linnemann Jensen M; IQVIA Solutions Denmark A/S, Copenhagen, Denmark.
  • Hoti F; IQVIA, Espoo, Finland.
  • Klement R; IQVIA, Tartu, Estonia.
  • Déruaz-Luyet A; Boehringer Ingelheim International GmbH; Binger Strasse 173, Ingelheim 55216, Germany.
  • Kyaw MH; Boehringer Ingelheim International GmbH, United States.
  • Koeneman L; Lilly Deutschland GmbH, Bad Homburg, Germany.
  • Vistisen D; Steno Diabetes Center Copenhagen, Herlev, Denmark; Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Carstensen B; Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Halvorsen S; Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway.
  • Langslet G; Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.
  • Fazeli Farsani S; Boehringer Ingelheim International GmbH; Binger Strasse 173, Ingelheim 55216, Germany. Electronic address: soulmaz.fazeli_farsani@boehringer-ingelheim.com.
  • Patorno E; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Núñez J; Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain.
Diabetes Metab ; 49(2): 101418, 2023 03.
Article in En | MEDLINE | ID: mdl-36608816
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / Sodium-Glucose Transporter 2 Inhibitors / Hypoglycemic Agents Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Asia / Europa Language: En Journal: Diabetes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2023 Document type: Article Affiliation country: Israel Country of publication: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / Sodium-Glucose Transporter 2 Inhibitors / Hypoglycemic Agents Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Asia / Europa Language: En Journal: Diabetes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2023 Document type: Article Affiliation country: Israel Country of publication: France